Right Ventricular Pacing in Pulmonary Arterial Hypertension
NCT04194632 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2021-05-03
Summary
In pulmonary arterial hypertension (PAH), progressive pulmonary vascular remodeling leads to supraphysiologic right ventricular (RV) afterload. Pharmacologic trials have shown that aggressive upfront treatment reversing pulmonary vascular remodeling successfully increases RV function and improves survival. To date, however, there are no proven treatments that target RV contractile function.
Echocardiographic studies of RV dysfunction in the setting of pressure overload have demonstrated intra and interventricular dyssynchrony even in the absence of overt right bundle branch block (RBBB).
Electrophysiologic studies of patients with chronic thromboembolic disease (CTEPH) at the time of pulmonary endarterectomy have shown prolongation of action potential and slowed conduction in the right ventricle which has correlated with echocardiographic measures of dyssynchrony.
Cardiac MRI measures of RV strain in patients with PAH demonstrated simultaneous initiation of RV and left ventricular (LV) contraction, but delayed peak RV strain suggesting that interventricular dyssynchrony is a mechanical rather than electrical phenomenon.
Prior studies of RV dysfunction in an animal model, computer model, congenital heart disease, and CTEPH have suggested acute hemodynamic benefits of RV pacing. However, RV pacing has not been studied in patients with PAH. Furthermore, it remains unclear if pacing particular regions of the RV can achieve a hemodynamic benefit and what cost this hemodynamic improvement may incur with regards to myocardial energetics and wall stress.
Therefore, the investigators propose to examine RV electrical activation in PAH, map the area of latest activation, and then evaluate the hemodynamic and energetic effects of RV pacing in these patients.
Conditions
- Pulmonary Artery Hypertension
- Right Ventricular Dysfunction
Interventions
- PROCEDURE
-
Temporary right ventricular pacing
As described previously. Patients will undergo temporary pacing at the site of latest endocardial activation with measurement of hemodynamic effects.
Sponsors & Collaborators
-
University of California, San Francisco
lead OTHER
Principal Investigators
-
Liviu Klein, MD · University of California, San Francisco
-
Benjamin W Kelemen, MD · University of California, San Francisco
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-01-01
- Primary Completion
- 2021-12-05
- Completion
- 2021-12-05
Countries
- United States
Study Locations
More Related Trials
-
Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension
NCT02782052 ·Status: WITHDRAWN ·Phase: PHASE3
-
Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension
NCT02080533 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
NCT05439460 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)
NCT04813926 ·Status: COMPLETED
-
HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)
NCT06084559 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension
NCT03554291 ·Status: COMPLETED ·Phase: PHASE2
-
Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Right Heart Catheterization With Acute Vasodilator Testing
NCT01275690 ·Status: WITHDRAWN
-
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
NCT04954742 ·Status: TERMINATED ·Phase: PHASE4
-
Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes
NCT03081052 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
NCT02554903 ·Status: COMPLETED ·Phase: PHASE2
-
Acute Effects of rhBNP in Patients With PH Associated With Acute Exacerbation of Chronic Pulmonary Disease
NCT02742909 ·Status: COMPLETED ·Phase: PHASE4
-
Carvedilol PAH A Pilot Study of Efficacy and Safety
NCT02120339 ·Status: TERMINATED ·Phase: PHASE1
-
PAH Exercise Study
NCT06941441 ·Status: RECRUITING ·Phase: PHASE3
-
Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin
NCT05060315 ·Status: TERMINATED
-
Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
NCT03015402 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
NCT02847260 ·Status: COMPLETED ·Phase: PHASE4
-
Patient Reported Outcomes in Pulmonary Arterial Hypertension
NCT01792622 ·Status: WITHDRAWN
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
NCT00423202 ·Status: COMPLETED ·Phase: PHASE3
-
Neuromodulation in Patients With Pulmonary Arterial Hypertension
NCT06802380 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Medication Reconciliation in Pulmonary Hypertension
NCT04744584 ·Status: COMPLETED
-
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
NCT07073820 ·Status: RECRUITING ·Phase: PHASE2
-
Assessing the Utility of Submaximal CPET in Treatment Management of PAH
NCT05977933 ·Status: NOT_YET_RECRUITING
-
Integrated Diagnostics Characterization of Right Ventricular Diastolic Flow Dynamics in Pulmonary Arterial Hypertension
NCT01491646 ·Status: COMPLETED
-
Trimetazidine in Pulmonary Artery Hypertension
NCT02102672 ·Status: UNKNOWN ·Phase: PHASE2
-
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction
NCT00458042 ·Status: TERMINATED ·Phase: PHASE4